drugset / Trial / NCT06926075
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Timeline
- Start
- 2025-11-07
- Primary completion
- 2027-10-26
- Completion
- 2027-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KESONOTIDE | Unknown | 10 mg | Oral |
| Subject | KESONOTIDE | Unknown | 30 mg | Oral |
| Subject | KESONOTIDE | Unknown | 60 mg | Oral |
| Subject | KESONOTIDE | Unknown | 120 mg | Oral |